Uveitis: A potentially blinding disease

被引:227
作者
Durrani, OM
Meads, CA
Murray, PI
机构
[1] Univ Birmingham, Acad Unit Ophthalmol, Birmingham, W Midlands, England
[2] Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham, W Midlands, England
关键词
uveitis; epidemiology of uveitis; blindness; quality of life; cost of blindness;
D O I
10.1159/000078612
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Uveitis (intraocular inflammation) is a potentially blinding group of, probably autoimmune, conditions predominantly occurring in the working age group. Although the aetiology is unknown in most cases, many patients have an associated underlying systemic disease. Central vision loss, in the form of cystoid macular oedema, is the commonest type of visual impairment. Although historical incidence and prevalence data exists, little is known about the degree of vision loss experienced, and the social and financial consequences of having temporary or permanent visual impairment in this age group. The literature is also full of uncontrolled studies and case reports of different modalities of drug therapy for uveitis. This article attempts to raise the awareness of uveitis as an important sight-threatening group of conditions by highlighting the paucity of evidence-based data on epidemiological, quality of life, socioeconomic, and therapeutic aspects. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:223 / 236
页数:14
相关论文
共 178 条
[81]   What is the cost of blindness? [J].
Meads, C ;
Hyde, C .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2003, 87 (10) :1201-1204
[82]   Epidemiology of endogenous uveitis in north-eastern Italy; Analysis of 655 new cases [J].
Mercanti, A ;
Parolini, B ;
Bonora, A ;
Lequaglie, Q ;
Tomazzoli, L .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 2001, 79 (01) :64-68
[83]   Uveitis in the southeastern United States [J].
Merrill, PT ;
Kim, JH ;
Cox, TA ;
Betor, CC ;
McCallum, RM ;
Jaffe, GJ .
CURRENT EYE RESEARCH, 1997, 16 (09) :865-874
[84]  
MIETTINEN R, 1977, ACTA OPHTHALMOL, V55, P252, DOI 10.1111/j.1755-3768.1977.tb01306.x
[85]   Efficacy and safety of chlorambucil in intractable noninfectious uveitis - The Massachusetts eye and ear infirmary experience [J].
Miserocchi, E ;
Baltatzis, S ;
Ekong, A ;
Roque, M ;
Foster, CS .
OPHTHALMOLOGY, 2002, 109 (01) :137-142
[86]   Biodegradable scleral implant for intravitreal controlled release of fluconazole [J].
Miyamoto, H ;
Ogura, Y ;
Hashizoe, M ;
Kunou, N ;
Honda, Y ;
Ikada, Y .
CURRENT EYE RESEARCH, 1997, 16 (09) :930-935
[87]   A CLINICAL-TRIAL OF FK506 IN REFRACTORY UVEITIS [J].
MOCHIZUKI, M ;
MASUDA, K ;
SAKANE, T ;
ITO, K ;
KOGURE, M ;
SUGINO, N ;
USUI, M ;
MIZUSHIMA, Y ;
OHNO, S ;
INABA, G ;
MIYANAGA, Y ;
HAYASAKA, S ;
OIZUMI, K .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1993, 115 (06) :763-769
[88]   Cataract surgery in patients with uveitis [J].
Muccioli, C ;
Belfort, R .
INTERNATIONAL OPHTHALMOLOGY CLINICS, 2000, 40 (02) :163-173
[89]   Short-term chlorambucil for refractory uveitis in Behcet's disease [J].
Mudun, AB ;
Ergen, A ;
Ipcioglu, SU ;
Burumcek, EY ;
Durlu, Y ;
Arslan, MO .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2001, 9 (04) :219-229
[90]   SOLUBLE INTERLEUKIN-2 RECEPTORS IN RETINAL VASCULITIS [J].
MURRAY, PI ;
YOUNG, DW .
CURRENT EYE RESEARCH, 1992, 11 :193-195